Barclays
INBX icon

Barclays’s Inhibrx INBX Stock Holding History

Barclays’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
1,667
-20,212
-92% -$1.5M ﹤0.01% 3977
2025
Q4 		$1.73M Buy
21,879
+8,411
+62% +$573K ﹤0.01% 3045
2025
Q3 		$454K Sell
13,468
-3,696
-22% -$91K ﹤0.01% 3867
2025
Q2 		$245K Buy
17,164
+3,881
+29% +$50.2K ﹤0.01% 4157
2025
Q1 		$186K Sell
13,283
-5,558
-29% -$75.5K ﹤0.01% 4086
2024
Q4 		$290K Buy
18,841
+2,786
+17% +$42.4K ﹤0.01% 4136
2024
Q3 		$251K Buy
16,055
+12,476
+349% +$175K ﹤0.01% 4182
2024
Q2 		$50.7K Buy
+3,579
New +$55.9K ﹤0.01% 4210

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays's INBX Position: Q1 2026 in Review

Barclays reduced its Inhibrx (INBX) stake by 92% in Q1 2026, selling an estimated $1.5M and leaving 1,667 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #3977.

Barclays first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.73M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Barclays held 1,667 shares of Inhibrx worth $112K as of Q1 2026.
  • Barclays sold 20,212 Inhibrx shares in Q1 2026, an estimated $1.5M.
  • Inhibrx made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3977 holding.
  • Barclays first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Inhibrx position peaked at $1.73M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.